.Attributes Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a typical follow-up of 11 months, clients with metastatic gastrointestinal tumors who acquired biomarker-matched treatments based upon spreading tumor DNA profiling presented a better professional benefit than those receiving incomparable treatment.